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AngiogenesisThe transforming growth factor β (TGF-β) signaling pathway plays a key role in different physiological
processes such as development, cellular proliferation, extracellular matrix synthesis, angiogenesis or immune
responses and its deregulation may result in tumor development. The TGF-β coreceptors endoglin and
betaglycan are emerging as modulators of the TGF-β response with important roles in cancer. Endoglin is
highly expressed in the tumor-associated vascular endothelium with prognostic signiﬁcance in selected
neoplasias and with potential to be a prime vascular target for antiangiogenic cancer therapy. On the other
hand, the expression of endoglin and betaglycan in tumor cells themselves appears to play an important role
in the progression of cancer, inﬂuencing cell proliferation, motility, invasiveness and tumorigenicity. In
addition, experiments in vitro and in vivo in which endoglin or betaglycan expression is modulated have
provided evidence that they act as tumor suppressors. The purpose of this review was to highlight the
potential of membrane and soluble forms of the endoglin and betaglycan proteins as molecular targets in
cancer diagnosis and therapy.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Transforming growth factor β (TGF-β) is the prototypic member of
a large family of evolutionarily conserved secreted cytokines that also
includes activins and bone morphogenetic proteins (BMPs). Indivi-
dual family members play crucial roles in development and in the
regulation of tissue homeostasis during adult life [1,2]. Accordingly,
alterations to the signaling pathways activated by TGF-β family
members have been implicated in many human diseases, including
cancer, vascular, ﬁbrosis and autoimmune diseases [3–8].
1.1. The role of TGF-β in cancer
TGF-βplays adual andparadoxical role in cancer [3,9–11]. On theone
hand it acts as a tumor suppressor during the premalignant phase of
carcinogenesis, inhibiting cell growth and inducing apoptosis or
differentiation. On the other hand, cancer cells that have lost this
inhibitory growth response exploit the ability of TGF-β to modulate
processes such as cell invasion, angiogenesis, immune regulation, or
interactions between tumor cells and their microenvironment that
make them more malignant. The tumor suppressor and tumor
promoting effect of TGF-βmay be exerted on the tumor cells themselveslogicas, CSIC Ramiro deMaeztu
).
ll rights reserved.or indirectly by taking advantage of the interactions between the tumor
and stroma [12]. For example, TGF-β arrests the progression of epithelial
cells in the G1 phase of the cell cycle by mobilizing cyclin-dependent
kinase inhibitors (cdki) and downregulating c-Myc expression [13]. Yet
in addition to this direct effect on tumor cells, TGF-β can restrict
epithelial cell proliferation and tumor formation by preventing the
production of paracrine factors in stromal ﬁbroblasts [14], or by
constraining tumorigenic inﬂammation [15]. Some cancer cells evade
the tumor suppressor effects of TGF-β by accumulating inactivating
mutations in the TGF-β receptors and Smad proteins [16]. This is
particularly true for subsets of colorectal, pancreatic, ovarian, gastric,
and head and neck carcinomas. Interestingly, the BMP signaling
pathway may also be disrupted in cancer, and mutations in BMPR1A
are associated with juvenile polyposis syndrome (see below). However,
the core components of TGF-β signaling remain intact in themajority of
tumors (i.e., breast and prostate carcinomas, melanomas, gliomas and
hematopoietic neoplasias). Cells within these tumors avoid the tumor
suppressor activity of TGF-βbyavariety ofmechanisms that are not fully
understood and which lead to the loss of the TGF-β anti-proliferative
response [17]. For example, the p15INK4b locus is a downstream target
gene of TGF-β signaling that encodes a cdki involved in regulating the
cell cycle, and it is homozygously deleted in a subset of gliomas [18].
Other alterations thatmay contribute to the loss of the anti-proliferative
response in gliomas are PI3K hyperactivation or mutational inactivation
of the RB locus [19]. However, in many tumors that preserve an intact
TGF-β signaling pathway the precise mechanisms leading to the loss of
the TGF-β cytostatic response is unknown.
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respond to this growth factor by enhancing cell motility and
invasiveness. TGF-β is a potent inducer of the epithelial–mesenchymal
transition (EMT) [20,21], a phenotypic conversion by which epithelial
cells lose their polarity and cohesiveness (indeed, a hallmark of EMT is
the loss of the adherens junction protein E-cadherin), acquiring the
migratory features typical of ﬁbroblasts. EMTs are necessary for
morphogenetic processes during embryonic development but they
are also involved in pathological situations, such as ﬁbrosis, tumor
invasion and metastasis [22,23]. TGF-β can also promote tumor cell
growth by stimulating the production of autocrine mitogenic factors
[19]. Moreover, TGF-β contributes to tumor progression in the stroma
by regulating the generation of myoﬁbroblasts or “cancer-associated
ﬁbroblasts” frommesenchymal precursors, the evasion of the immune
surveillance, the stimulation of angiogenesis and the promotion of
distal metastasis [11,12].
In the last decade, several studies have documented a role for the
TGF-β type III receptors betaglycan and endoglin in cancer (see
Gordon and Blobe [5], for a recent review). These coreceptors not only
bind TGF-β, BMP and inhibin ligands and receptors, but they also
regulate their function by as yet unknown mechanisms. It is generally
believed that alterations of betaglycan and endoglin in cancer
contribute to the deregulation of TGF-β signaling. Nevertheless,
these coreceptors interact with proteins and signaling pathways
other than TGF-β and thus, they may have cellular effects that are
independent of TGF-β signaling.
1.2. The TGF-β receptor complex
The effects of the TGF-β family of soluble proteins in cancer are
exerted through speciﬁc receptor complexes present at the cell surface.
These receptor complexes contain heterodimeric type I and II receptorsFig. 1. The TGF-β signaling pathway. The members of the TGF-β family, which include TGF-β
that exhibit serine/threonine kinase activity. Accessory receptors endoglin and betaglycan, al
form of R-III can be generated by juxtamembrane proteolysis of the membrane bound recep
TGF-β signals via the ALK5/TβRII heterodimer. In other cell types, including endothelial cel
ALK4/ActRII, whereas BMPs signal via ALK1, ALK2, ALK3 or ALK6 as the R-I, and through BMP
speciﬁcity of the receptor complex. Thus, activated R-I phosphorylates speciﬁc R-Smads. M
Smad1, Smad5 and Smad8, while activation of ALK4, ALK5 and ALK7 phosphorylates Smad2 a
translocated to the nucleus and that regulate speciﬁc gene expression responses by bindin
Smads), Smad6 and Smad7, can interfere with R-Smad activation. ActR, activin receptor; ALK
GTM, general transcription machinery; Sol-R-III, soluble endoglin/betaglycan; TβR, TGF-β rthat constitute the core signaling complex, as well as type III receptors
that include the auxiliary molecules endoglin and betaglycan (Fig. 1).
Membrane bound and soluble forms of endoglin and betaglycan can
modulate signalingbybinding to the ligandand to the type I and II TGF-β
receptors. The type I and II receptors are serine/threonine kinases
involved in downstream signaling, whereas the coreceptors are proteins
with no known signaling motifs. The core TGF-β signaling pathway
comprises at least seven type I (also known as activin-like kinase
receptors) and ﬁve type II receptors, where type I receptors act
downstream of type II receptors, and the combinatorial heterodimeric
association of these receptors determines the speciﬁcity of the ligand
signaling [1,2]. Thus, ligand binding to the type II receptor activates and
transphosphorylates the type I receptor,which subsequently propagates
the signal by phosphorylating the receptor-regulated Smad (R-Smad)
family of proteins. Upon activation, R-Smad proteins form heteromeric
complexes with a cooperative homologue named Co-Smad (Smad4 in
mammals), and they are translocated into the nucleus where they
regulate the transcriptional activity of target genes (Fig. 1).
Although there are other TGF-β superfamily coreceptors such as the
members of the repulsive guidance family of glycosylphosphatidylino-
sitol-anchored proteins DRAGON, RGMa, and hemojuvelin [24–26], or
the member of the α2-macroglobulin/C3, C4, C5 family of thioester-
containing proteins, CD109 [27], their role in cancer is still unclear.
Therefore, in this reviewwewill focus on the role of the transmembrane
protein coreceptors endoglin and betaglycan in the TGF-β system.
2. The TGF-β coreceptors endoglin and betaglycan
2.1. Structure/Function relationship
Human endoglin and betaglycan are type I integral membrane
proteins with large extracellular domains (561 and 766 amino acids,s, activins and BMPs, bind to speciﬁc type I (R-I) and type II (R-II) cell surface receptors
so known as type III (R-III) receptors, modulate TGF-β signaling via R-I and R-II. A soluble
tor that can sequester ligands and thereby inhibit their binding to R-I/R-II. In most cells
ls, ALK1, another R-I, also mediates TGF-β signaling via ALK1/TβRII. Activins signal via
RII or ActRII as the R-II. The R-I acts downstream of R-II and it determines the signaling
ore speciﬁcally, activation of ALK1, ALK2, ALK3 and ALK6 leads to phosphorylation of
nd Smad3. Activated R-Smads associate with Smad4 in heteromeric complexes that are
g to DNA together with other DNA binding transcription factors. Inhibitory Smads (I-
, activin receptor-like kinase; BMP, bone morphogenetic protein; BMPR, BMP receptor;
eceptor.
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short cytoplasmic domains (47 and 42 residues, respectively)
[28,29]. Endoglin and betaglycan are independently expressed as
homodimeric glycoproteins, although a minor subset of heteromeric
complexes of endoglin and betaglycan have been detected in
endothelial cells [30]. In the case of endoglin, the monomers are
disulphide-linked, whereas the betaglycan dimer is sustained by non-
covalent interactions (Fig. 2). Endoglin and betaglycan are transmem-
brane proteins that share a degree of sequence similarity. Conse-
quently, the initial search for functional attributes of endoglin has
drawn upon previous results from the study of betaglycan in the TGF-
β system. Endoglin shares a high degree of amino acid sequence
homology with betaglycan in the transmembrane and cytoplasmic
domains. Indeed, the cytoplasmic domain of these proteins constitu-
tes the most highly conserved region among homologous members
from different mammalian species, as well as between endoglin and
betaglycan [31]. The in vivo expression of 2 different alternatively
spliced isoforms, long (L)-endoglin and short (S)-endoglin, has been
demonstrated in human and mouse tissues [32–34]. Both isoforms
share common extracellular and transmembrane domains, but they
differ from each other in the composition of their cytoplasmic domain.
In humans, L-endoglin contains a cytoplasmic domain of 47 residues,
whereas S-endoglin contains a cytoplasmic domain of 14 residues.
Because L-endoglin is muchmore prevalent than S-endoglin andmost
functional studies have been carried out with L-endoglin, no further
reference to the endoglin isoforms will be made in this review. At
variance with endoglin, no alternatively spliced isoforms have so far
been described for betaglycan.
The cytoplasmic domains of both endoglin and betaglycan can be
phosphorylated by serine/threonine kinases, including the TGF-β
type I and II receptors [35–39]. Endoglin phosphorylation might be a
Smad-independent mechanism to regulate the inﬂuence of endoglin
in cell growth and adhesion. In fact, it has been shown that endoglin
phosphorylation inﬂuences its subcellular localization, potentially by
modulating endoglin's interactions with adhesive proteins such as
zyxin and ZRP-1, thereby modifying the adhesive properties of
endoglin-expressing cells [37]. The regulation and pattern of endoglin
phosphorylation by the TGF-β receptors are complex. A detailed study
was carried out of endoglin phosphorylation by constitutively active
(ca) forms of the TGF-β receptors, caALK1, caALK5 and wild type
TβRII. Site-directed mutagenesis of endoglin suggests that caALK5 and
TβRII phosphorylate the 634SerSer635 motif within endoglin's cyto-
plasmic domain, whereas ALK1 preferentially phosphorylates wildFig. 2. Structural representation of type III TGF-β receptors. Endoglin and betaglycan are typ
domain (ZPD) of 260 amino acids in the juxtamembrane region and an N-terminal orphan do
endoglin monomers are disulphide-linked, the betaglycan dimer is sustained by non-cova
glycosaminoglycans to the extracellular domain have been identiﬁed. Both endoglin and bet
consensus PDZ-binding motifs present at the carboxyl terminus. The cytoplasmic (CYT), t
scheme is not to scale.type endoglin at threonine residues. Interestingly, mutation of the
634SerSer635 residues to 634AlaAla635 strongly reduces threonine
phosphorylation of endoglin, suggesting that phosphorylation of
634SerSer635 is a prerequisite for subsequent endoglin threonine
phosphorylation. This hypothesis was conﬁrmed by replacing one
mutated alanine with a phospho-mimicking aspartate residue
(634AspAla635), which restores threonine phosphorylation by caALK1
[37].
Both endoglin and betaglycan cytoplasmic domains contain
consensus PDZ-binding motifs at their carboxyl terminus (SerSerMe-
tAla and SerSerThrAla, respectively; Fig. 2). Studies of speciﬁc
mutations have been informative about the role of PDZ domains and
for example, betaglycan can alter the subcellular localization of the
signaling receptor complex by interacting with the PDZ domain
containing proteins, GIPC [40] and β-arrestin2 [38]. Also, the removal
of endoglin's putative C-terminal PDZ-binding motif results in
endoglin hyperphosphorylation of distal threonine residues [37].
These data indicate that receptor-mediated phosphorylation of
endoglin is a complex process involving negative regulation by the
PDZ-bindingmotif and an unexpected sequential mechanism of serine
and threonine phosphorylation.
Yeast two-hybrid and cell biology approaches identiﬁed zyxin and
the zyxin-related protein 1 (ZRP-1) as the ﬁrst cytosolic proteins that
interact with endoglin's cytoplasmic domain [41,42]. Because these
interactions occur with endoglin's cytoplasmic domain, which con-
tains serine/threonine phosphorylation sites [37], protein–protein
interactions involving this endoglin domain are likely to be regulated
by phosphorylation. The interaction between endoglin and the zyxin-
related proteins is exclusive since the latter does not appear to interact
with betaglycan, even though their cytoplasmic domains are 70%
identical [41,42]. However, endoglin does associate with proteins that
also interact with betaglycan. For example, β-arrestin2 interacts with
the conserved distal end of the betaglycan cytoplasmic domain and it
regulates betaglycan internalization [38]. This interaction also occurs
with the endoglin cytoplasmic domain, resulting in the internalization
of endoglinwith β-arrestin2 into endocytic vesicles [43]. Furthermore,
the betaglycan/endoglin endocytosis mediated by β-arrestin2, dam-
pens TGF-β signaling [38,43]. More recently, it has been shown that
betaglycan undergoes endocytosis in a ligand- and glycosaminogly-
can-independent manner, but dependent on its cytoplasmic domain
[44]. Moreover, the interaction of Thr841 in the cytoplasmic domain of
betaglycan with β-arrestin2 enhances betaglycan endocytosis. Inter-
estingly, betaglycan undergoes both clathrin-mediated and clathrin-e I membrane proteins with a large extracellular domain that contains a zona pelucida
main (OD) with no known homology. Both endoglin and betaglycan form dimers. While
lent interactions. Consensus motifs to attach N-linked glycans, O-linked glycans and
aglycan cytoplasmic domains are phosphorylated at Ser/Thr residues and they contain
ransmembrane (TM) and extracellular (EC) domains of the protein are indicated. The
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pendent, lipid raft pathway, but not that of the clathrin-dependent
pathway, decreased TGF-β1 induced Smad2 and p38 phosphorylation,
suggesting a speciﬁc role for clathrin-independent endocytosis of
betaglycan in regulating both Smad-dependent and Smad-indepen-
dent TGF-β signaling [44].
The cytoplasmic domain of endoglin also interacts with a member
of the Tctex1/2 family of cytosolic dynein light chains, Tctex2β, linking
endoglin to the microtubule-based transport machinery [45]. Inter-
estingly, Tctex1 is phosphorylated by the type II BMP receptor, BMPRII
[46], further supporting a functional linkage between Tctex proteins,
endoglin and TGF-β receptor complexes. Together, these studies
suggest the endoglin cytoplasmic domain is involved in different
protein–protein interactions that modulate endoglin function.
Although endoglin and betaglycan extracellular domains share
limited homology, they do share the presence of a zona pellucida (ZP)
consensus motif in the juxtamembrane region (Fig. 2). Comparative
analysis of their primary structure reveals that endoglin and
betaglycan belong to the ZP family of extracellular proteins that
share a ZP domain consisting of 260 amino acids with 8 conserved
cysteine residues close to the transmembrane region [47,48]. This
consensus ZP domain is divided in two ZP subdomains (ZP-N and ZP-
C) that are potentially involved in receptor oligomerization [48,49].
Human endoglin, but not betaglycan, contains an RGD tripeptide
located in the ZP domain of the extracellular region [28]. Although this
RGD motif led to the hypothesis that endoglin binds to integrins or
other RGD-binding receptors [50,51], the presence of the RGD
sequence in human endoglin may be a recent adaptation, as this
motif is absent from mouse [52], porcine [53], rat and canine [49]
endoglin proteins. The primary structure of endoglin suggests that
there are four N-linked glycosylation sites in the N-terminal domain
and a probable O-glycan domain rich in Ser and Thr residues proximal
to themembrane-spanning domain [28] (Fig. 2). Experimental studies
using speciﬁc glycosidases conﬁrmed that endoglin is glycosylated
[54]. This post-translational modiﬁcation occurs in multiple stages
when endoglin is overexpressed in COS cells, giving rise to partiallyFig. 3. Three-dimensional model of endoglin. (A) The atomic model predicted in silico shows
contains amino acid residues Glu26-Ile359 (red), whereas the ZP domain encompasses the f
respectively. The amino acid numbers corresponding to the border regions of the globular do
volume) allows an atomic model of dimeric endoglin to be ﬁtted. (C) Cartoon model for the d
Llorca et al. [49].and fully glycosylated species that are present at the cell surface [55].
Betaglycan is an integral membrane proteoglycan with an average
mass of 280–330 kDa, of which 200-kDa corresponds to glycosami-
noglycans and 10 kDa to N-linked glycans attached to the extracellular
domain of a heterogeneous core polypeptide of 100–120 kDa [56].
Most of the betaglycan proteins contain heparan sulphate and
chondroitin sulphate in varying proportions [57]. Interestingly, the
Ser533Ala and Ser544Ala mutations in murine betaglycan yield a
betaglycan devoid of glycosaminoglycan chains [58].
The three-dimensional structure of the extracellular region of
endoglin was determined at a resolution of 25 Å using single-particle
electron microscopy [49]. The molecular reconstruction suggests that
endoglin exists as a dome comprised of anti-parallel orientated
monomers enclosing a cavity at one end (Fig. 3). Using these data, the
high-resolution structure of endoglin suggests that each endoglin
subunit comprises three well deﬁned domains, the two ZP regions
(ZP-N and ZP-C) and one orphan domain, which are organized into an
open U-shaped monomer [49] (Fig. 3). Recently, small angle X-ray
scattering experiments of soluble endoglin revealed a more elongated
conformation for the dimer, suggesting that the protein may undergo
conformational adaptation upon ligand binding [59]. Unfortunately,
no data are available regarding the three-dimensional structure of
betaglycan.
2.2. Regulation of TGF-β ligand access to receptors
Endoglin is predominantly expressed in vascular endothelial cells,
while betaglycan is more ubiquitously distributed. Betaglycan, is a
major TGF-β binding molecule at the cell surface and it binds multiple
members of the TGF-β family with high afﬁnity, including TGF-β1,
TGF-β2, TGF-β3, Activin-A, BMP-2, BMP-4, BMP-7, and GDF-5
[56,60,61]. Betaglycan interacts with the type II TGF-β receptor and
it plays a role in presenting the ligand to TβRII, either inhibiting or
enhancing signaling through mechanisms that are yet to be deﬁned
[31,62–65]. TGF-β binds to the N-terminal endoglin-related region of
betaglycan, and mutational analyses suggest that the remainingthe presence of three different subdomains in red, yellow and blue. The orphan domain
ragment Gln360-Gly586. The ZP-N and ZP-C subdomains are colored in yellow and blue,
mains are indicated. (B) The electron microscopy density map of soluble endoglin (grey
omain organization of endoglin within the dimer (domain colors as in A). Adapted from
Table 1
Endoglin and betaglycan interacting proteins⁎.
R-III domain TGF-β superfamily
members
R-I R-II Cytoplasmic
proteins
Endoglin-ECD TGF-β1, TGF-β3,
activin-A, BMP-2,
BMP-7, BMP-9,
BMP-10
ALK1, ALK2,
ALK3, ALK5,
ALK6
TβRII,
ActRII,
BMPRII
Betaglycan-ECD TGF-β1, TGF-β2,
TGF-β3, activin-A,
inhibin-A, BMP2,
BMP4, BMP7, GDF-5
Endoglin-CD ALK1, ALK5 TβRII Zyxin, ZRP-1/
TRIP-6,
β-Arrestin2,
Tctext2β
Betaglycan-CD TβRII GIPC,
β-arrestin2
⁎Proteins interacting with the extracellular (ECD) and cytoplasmic (CD) domains of
endoglin and betaglycan are indicated. This is a summary of different reports describing
protein–protein interaction, co-immunoprecipitation, cross-linking, phosphorylation,
and functional experiments, as indicated in the text.
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dependent enhancement of TGF-β binding to TβRII. However, protein
anchoring to the membrane is required [66]. The betaglycan
ectodomain is endowed with two bona ﬁde and independent
ligand-binding domains that can perform speciﬁc functions as
coreceptors of distinct members of the TGF-β superfamily [67]. Early
studies on the primary structure of betaglycan revealed a strong
homology with endoglin in the cytoplasmic and transmembrane
domains [31], suggesting that endoglin was also a component of the
TGF-β receptor system. In fact, it was established that endoglin binds
TGF-β1 and TGF-β3 but not TGF-β2 [68], distinguishing it from
betaglycan. These studies provided the basis to examine endoglin's
functions as a component of the TGF-β receptor system. Because
endoglin differs from betaglycan in its TGF-β ligand-binding proﬁle
[68], it was not surprising to learn that both functional differences and
similarities exist between these two proteins. An exclusive role for the
extracellular TGF-β ligand-binding domain was evident when
cytoplasmic domains of endoglin and betaglycan were switched,
which had no effect on endoglin ligand binding [69]. However, in
contrast to betaglycan, the binding of TGF-β1, activin-A, BMP-7 and
BMP-2 to endoglin requires the presence of the corresponding type II
receptor [69,70], suggesting that endoglin participates in the binding
of these ligands only within the TGF-β receptor complex. This
behavior would explain why only a small fraction of the total cell
surface endoglin binds TGF-β1 [68]. However, there are other data
supporting the independent ligand-binding capacity of the extra-
cellular domain of endoglin and indeed BMP-9 appear to bind
membrane anchored endoglin in the absence of signaling receptors
[71], while a soluble form of endoglin has been shown to sequester
TGF-β [72].
2.3. Endoglin and betaglycan in the TGF-β receptor complex
Endoglin bound to ligand can be isolated as a complex with type I
and type II TGF-β receptors [68]. The type I receptors include ALK1, the
BMP receptors ALK2, ALK3 and ALK6, as well as ALK5 and the activin
receptors, ALK2 and ALK4. In addition, various type I receptors can
interact with the type II TGF-β (TβRII), activin (ActRII) or BMP
(BMPRII) receptors [1,4,5]. In vitro co-immunoprecipitation studies of
endoglin with type I and type II receptors indicate that endoglin
interacts with TGF-β1, TGF-β3, activin-A, BMP-7 and BMP-2 ligands
[53,68–70]. These results are supported by functional experiments, at
least in the case of BMP-7, demonstrating that endoglin overexpres-
sion enhances the BMP-7/Smad1/Smad5 pathway, while inhibiting
the TGF-β1-induced ALK5/Smad3 signaling [73,74]. As discussed
above, these interactions require co-expression of the respective
ligand-binding kinase receptors [69,70]. Accordingly, endoglin binds
TGF-β1 and TGF-β3 by associating with TβRII, and it interacts with
activin-A and BMP-7 in association with the ActRII receptors ActRIIA
and ActRIIB. Also, endoglin binds BMP-2 by interacting with the BMP
ligand-binding receptors ALK3 and ALK6 [70]. Interestingly, BMP-9
binds with high afﬁnity to endoglin in the absence of TGF-β signaling
receptors [71]. Accordingly, overexpression of endoglin increases the
BMP-9 response, whereas it is completely abolished by silencing both
BMPRII and ActRIIA expression [75]. These studies indicate that
endoglin binds to most ligand-type I/II receptor complexes, poten-
tially reﬂecting a role for endoglin in the dynamics of type I/II receptor
interactions and their downstream signaling pathways.
Studies of the interaction of endoglinwith ALK5 and TβRII indicate
that both ALK5 and TβRII interact with the extracellular and
cytoplasmic domains of endoglin. However, ALK5 only interacts
with the endoglin cytoplasmic domain when the kinase domain is
inactive. Upon association, ALK5 and TβRII phosphorylate the
endoglin cytoplasmic domain and then, ALK5 but not TβRII,
dissociates from the complex [36]. Thus, phosphorylated endoglin,
as a consequence of the Ser/Thr kinase activation, appears to play aregulatory role in the TGF-β receptor complex. Together, these data
suggest that the extracellular and cytoplasmic domains of endoglin
and betaglycan play distinct roles in receptor signaling downstream of
ligand binding and receptor activation. Table 1 summarizes the
proteins identiﬁed to date that interact with the extracellular and
cytoplasmic domains of endoglin and betaglycan, including TGF-β
superfamily members, type I and type II TGF-β receptors, and some
cytoplasmic proteins.
2.4. Endoglin and betaglycan in TGF-β-dependent cell responses
Endoglin modulates TGF-β-dependent responses in several cell
types. In human monocytic U-937 cells, responses to TGF-β1, but not
toTGF-β2, are abrogated in the presence of endoglin [76]. Moreover, in
a variety of cell types, including myoblasts vascular endothelial cells,
monocytes and ﬁbroblasts, endoglin opposes to TGF-β1-dependent
responses such as the inhibition of cellular proliferation, the induction
of apoptosis, cellular adhesion or homotypic cell aggregation, and the
increased expression of extracellular matrix components such as
plasminogen activator inhibitor-1 (PAI-1), collagen and ﬁbronectin
[69,76–81], as well as the secreted extracellular matrix-associated
protein lumican [82]. Interestingly, no changes in total ligand binding
were observed in endoglin cell transfectants [76], suggesting that
endoglin's effects occur downstream of ligand binding. Like TGF-β
receptor signaling in general, the regulatory effects of endoglin are
likely to be cell type speciﬁc, subject to conditions that include the
speciﬁc type I and type II TGF-β receptors present and the relative
levels of endoglin.
Although TGF-β is a potent inhibitor of cell proliferation, endoglin
expression counteracts this inhibitory effect in several cell types,
including endothelial cells [76,80]. The positive correlation between
endoglin expression and endothelial cell proliferation was conﬁrmed
in several experimental models. Indeed, endoglin is markedly
upregulated in proliferating endothelium of tissues undergoing
angiogenesis [83–87] and in vitro inhibition of its expression in
endothelial cells impairs this process [80]. In addition, suppression of
endoglin not only increases the TGF-β1-dependent inhibition of
endothelial cell proliferation but also, endothelial cell apoptosis
induced by hypoxia and TGF-β1 [81]. Furthermore, in mice bearing
targeted endoglin (Eng) alleles, studies of Eng−/− and Eng+/−
embryonic endothelial cells indicate that endoglin promotes endothe-
lial cell proliferation via a TGF-β/ALK1 pathway [88].
How endoglin regulates these TGF-β-dependent responses is
unknown. A potential mechanism of action is via endoglin-dependent
effects on TGF-β receptor phosphorylation. TβRII is thought to be a
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phosphorylation upon ligand-induced association. Betaglycan func-
tions by selectively binding the phosphorylated TβRII through its
cytoplasmic domain to promote TGF-β2 signaling [39]. Interestingly,
endoglin association with TβRII alters the phosphorylation state of
TβRII and provokes the loss of ALK5 from the complex [36]. Either of
these events could explain the inhibitory effects of endoglin on ALK5
signaling, which requires phosphorylation by the TβRII kinase after its
association with TGF-β1. Additionally, studies in primary human
umbilical vein endothelial cells suggest that endoglin phosphorylation
opposes the activated ALK1-dependent inhibition of cell adhesion
[37]. These results suggest that endoglin might affect TGF-β responses
by interacting with the signaling receptors through its extracellular
and cytoplasmic domains.
As endoglin directly interacts with a variety of TGF-β type I
receptors [36,70,89], endoglin may exert additive or opposing effects
on TGF-β receptor signaling. Thus, although endoglin inhibits TGF-β/
ALK5/Smad3 cellular responses [69,73,88–90], it enhances ALK5/
Smad2 signaling [36,91,92]. In addition, endoglin may be required for
TGF-β1/ALK1 signaling in some cell types, especially endothelial cells.
This balance between ALK5 and ALK1may play a role in the regulation
of cell growth and differentiation in cells that express endoglin, as well
as ALK1 and ALK5 [88]. Themechanism bywhich endoglin potentiates
TGF-β/ALK1 signaling appears to involve direct association of ALK1
with the cytoplasmic and extracellular domains of endoglin, the
extracellular domain mediating the enhancement of ALK1 signaling
[89]. These studies suggest that the functional association of endoglin
with ALK1 is critical for endothelial cell responses to TGF-β. Such a
conclusion would agree with the fact that ALK1 and endoglin null
mice have similar phenotypes [93–97], and that the pathogenic
mutation of either human endoglin (ENG) or ALK1 (ACVRL1) genesFig. 4. Hypothetical model for downstream endoglin signaling. The endoglin extracellular an
arrows. Endoglin modulates TGF-β signaling by potentiating ALK1/Smad1 and ALK5/Smad2
regulation of Id1 [88,89], eNOS [92,104] and PAI-1 genes [69,36], respectively. The involvem
domain interacts with the β-arrestin, Tctex2b, zyxin, and ZRP-1 proteins [37,41,43,45]. Th
dynamics, focal adhesion composition, and protein transport via endocytic vesicles. As descri
from Bernabeu et al. [74,89].results in hereditary hemorrhagic telangiectasia (HHT) [98,99]. HHT,
also termed Osler-Weber-Rendu syndrome, is a dominant vascular
dysplasia associated with frequent epistaxis, gastrointestinal hemor-
rhages, cutaneous telangiectasis and arteriovenous malformations in
lung, liver and brain (OMIM #187300 and #600376) [100–102].
Together, these data provide additional support for endoglin acting
with ALK1 in the same TGF-β pathway. At variance with this
interpretation, it was reported that ALK1/Smad1/5/8 activation is
enhanced in endoglin null endothelial cells, suggesting that endoglin
is not required for TGF-β-dependent activation of ALK1 [103].
Endoglin stabilizes the Smad2 protein, potentially via a reduction
in the levels of the Smad ubiquitination response factor 2, Smurf2 [92].
Thus, in the presence of endoglin Smad2 protein levels increase
leading to TGF-β receptor-dependent induction of eNOS mRNA
expression and enhanced Smad-dependent signaling. Through the
endoglin-dependent regulation of eNOS [104,105], changes in nitric
oxide levels alter COX-2 expression and thus underlying the role of
endoglin in vascular homeostasis [106].
A schematic model to summarize the modulatory role of endoglin
in the TGF-β signaling pathways is depicted in Fig. 4. Endoglin
physically interacts with ALK1 and ALK5, functionally modulating
their signaling and leading to the potentiation of Smad1 and Smad2, as
well as the inhibition of Smad3, which regulate the expression of the
Id1, eNOS, and PAI-1 genes, respectively. Studies of the downstream
genes affected by endoglin expression have been carried out by gene
expression ﬁngerprinting of endoglin deﬁcient human endothelial
cells from HHT patients. These studies identiﬁed hundreds of genes
that were downregulated or upregulated, including genes involved in
angiogenesis, cytoskeleton organization, cell guidance, intercellular
connections, cell migration and proliferation, or nitric oxide synthesis
[107,108].d cytoplasmic domains interact with ALK1 [89] and ALK5 [36], as indicated with brown
(green arrows), and inhibiting the ALK5/Smad3 (red arrow) pathways that lead to the
ent of TβRII and TGF-β has been omitted for simpliﬁcation. The endoglin cytoplasmic
ese cytosolic interactions probably mediate downstream functions, including F-actin
bed in the text, some of these endoglin functions are also shared by betaglycan. Adapted
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In contrast to betaglycan, which is the most abundantly
expressed TGF-β receptor, endoglin is primarily expressed in
proliferating vascular endothelial and smooth muscle cells, and its
expression increases during tumor angiogenesis and inﬂammation.
Such properties have made endoglin a reliable marker of tumor
angiogenesis and a prime target for antiangiogenic therapy
[109–111]. Besides the proangiogenic role of endoglin, there is also
evidence of its direct involvement in cancer through its effects on
tumor cells themselves. Thus, recent studies on human cancer cell
lines and experimental models of carcinogenesis have linked
endoglin to malignant progression, suggesting an invasion suppres-
sor role for this coreceptor in carcinomas. In addition, endoglin has
been associated with a hereditary cancer disorder: juvenile poly-
posis syndrome. In this section, we will address the role of endoglin
in each of these settings.
3.1. Endoglin in tumor angiogenesis
3.1.1. Endoglin staining as a marker of tumor neoangiogenesis
While endoglin is expressed at low levels in resting endothelial
cells, it is more strongly expressed in vascular endothelial cells at sites
of active angiogenesis during embryogenesis [112], in inﬂamed tissues
of healing wounds [113], upon arterial injury [114,115], in infected
tissues, psoriatic skin, inﬂamed synovial arthritis and in tumor vessels
[84,112,116–120]. Endoglin is also overexpressed after ischemia and
reperfusion in the kidney [121], hindlimbs [122] and heart [123]. The
mechanisms involved in this enhancement of endoglin levels are
probably multifactorial, hypoxia being one of the most suitable
candidates. In fact, many of the pathophysiological settings where
endoglin is upregulated involve hypoxic microenvironments, as is the
case of tumor angiogenesis. In favor of this view, a hypoxia-responsive
element (HRE) has been characterized downstream of the main
transcription start site in the endoglin gene and under hypoxic
conditions, the HIF-1 complex binds this functional HRE upregulating
endoglin promoter activity [124]. Interestingly, TGF-β potently
stimulates endoglin expression via Smads [76,125,126] and in synergy
with the hypoxia pathway [124]. This transcriptional synergism
appears to be mediated by a multi-protein complex that includes
HIF-1α/HIF-1β, Smad3/Smad4 and Sp1, bound to their cognate DNA
binding motifs.
Elevated expression of endoglin correlates with the proliferation of
tumor endothelial cells [116] and it seems to be a potent marker of
solid tumors vasculature in the mammary gland [109], prostate [127],
cervix [128], colon and rectum [129,130], lung [131], head and neck
[132], kidney [133], esophagus [134] and uterus [135]. This has been
also observed in hematopoietic tumors such as multiple myeloma
[136] and in hairy cell leukemia [137]. Furthermore, an active role for
endoglin in the angiogenic process is supported by experiments in
animal models. Thus, reduced angiogenic responses and tumor
angiogenesis have been demonstrated in endoglin haploinsufﬁcient
mice [122,138].
3.1.2. Prognostic value of endoglin staining in microvessels
It has been reported that microvessel density (MVD) is an
independent prognostic indicator of the outcome for several human
tumors, as increased MVD was associated with shorter overall and
relapse-free survival rates [139–141]. However, these ﬁndings have
not always been conﬁrmed [142,143] and some such discrepancies
may be explained by the use of different antibodies against
endothelial markers to determine MVD, even though not all the
markers are associated with tumor neoangiogenesis. For instance,
while antibodies against the von Willebrand factor (vWF) stain
endothelial cells in large blood vessels, they fail to stain endothelial
cells in some microvessels and thus the use of these antibodieswould underestimate microvascular density in tumors. As previously
described, while endoglin is expressed at low levels in endothelial
cells of quiescent vasculature, it is overexpressed during angiogen-
esis. Thus, anti-endoglin antibodies should show greater speciﬁcity
for tumor microvasculature than other endothelial markers
[84,131,144–146]. Indeed, MVD measured with antibodies directed
against endoglin has been compared with the MVD measured with
antibodies against other endothelial markers such as CD34, CD31 or
vWF. In breast carcinoma, the MVD assessed with an anti-endoglin
antibody, but not with anti-CD34 was correlated with the overall
and disease-free survival, and it was an independent prognostic
factor in a multivariate analysis [147]. In non-small cell lung cancer
patients, the MVD obtained using an anti-endoglin antibody was
negatively correlated with survival [131]. Moreover, the MVD
obtained in colorectal mucosa with monoclonal anti-endoglin
antibodies (mAbs) was higher in the carcinoma than high-grade
dysplasia, and it was also higher in high-grade dysplasia than in
low-grade dysplasia, suggesting that endoglin-associated MVD
predicted the risk of progressing from dysplasia to carcinoma
[130]. In prostate cancer, the MVD score obtained with anti-endoglin
antibodies was associated with the Gleason score, metastasis, tumor
stage, tumor cell proliferation index and survival, although these
associations were not observed when antibodies against vWF were
used [148]. In patients with colorectal cancer, the MVD was
measured using antibodies against CD34 and endoglin, and
Kaplan-Meier survival analysis revealed that only MVD values
obtained with anti-endoglin antibodies were signiﬁcantly correlated
with survival. Furthermore, patients with a higher MVD showed the
worst prognosis [149], as later conﬁrmed in a study where endoglin
was a more speciﬁc and sensitive marker for tumor angiogenesis in
colon carcinoma than the commonly used pan-endothelial markers,
since it stained more proliferating vessels [150]. Endoglin staining
was also signiﬁcant in terms of prognosis due to its positive
correlation with angiolymphatic invasion and metastases to the
lymph nodes and liver [150]. In patients with early oral cancer,
strong expression of endoglin was signiﬁcantly correlated with
positive nodal metastasis and with a lower survival rate [151]. In
patients with Barrett's esophagus, a pre-tumor dysplasia, endoglin
staining gave a signiﬁcantly higher MVD in Barrett's esophagus with
high-grade dysplasia than in Barrett's esophagus low-grade dyspla-
sia, whereas the MVD obtained by CD31 staining showed no such
signiﬁcant differences [134]. Moreover, in patients with esophageal
or prostatic adenocarcinoma, endoglin but not CD31 staining had
prognostic value and it was positively correlated with the presence
of angiolymphatic invasion, lymphatic nodes metastases, tumor
stage and survival [134,152]. The expression of endoglin is also a
useful predictive prognostic factor in early tongue cancer, as
stronger expression of endoglin in the tumor bed implicates a
more aggressive potential for T1 and T2 tongue cancers [153].
Similar results were obtained in squamous cell carcinomas of the
hypopharynx [154]. In head and neck squamous carcinoma, the
disease-free and overall survival was signiﬁcantly shorter in patients
with a high MVD when assessed by endoglin staining. By contrast,
MVD assessed by CD34 staining was not associated with survival in
these same patients. Similarly, in the subset of lymph node negative
patients, higher endoglin-assessed MVD values were signiﬁcantly
associated with both disease-free and overall survival. A multi-
variate analysis showed that a high MVD when assessed by endoglin
staining was the only independent marker of tumor recurrence or
death [155]. In patients with breast carcinoma, and unlike staining
with anti-CD31 antibody on parafﬁn sections, staining with an anti-
endoglin antibody had prognostic signiﬁcance in terms of overall
survival [156]. In stage IB non-bulky (under 5 cm) cervical cancer
subjects, MVD assessed with anti-endoglin antibodies was more
sensitive than MVD using factor VIII antibodies to stain capillaries in
neoplastic tissues, and better predicted lymph node metastases
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patients, weak immunohistochemical endoglin expression predicts a
favorable clinical response to chemotherapy [158].
The better prognostic value of endoglinwhen comparedwith CD34
staining of microvessels has not been conﬁrmed for lymphopoietic
tumors. However, in patients with multiple myeloma, the staining
with anti-endoglin mAb was signiﬁcantly more sensitive than the
staining with anti-CD34 mAb in visualizing blood vessels both in
control and multiple myeloma samples, and the MVD was signiﬁ-
cantly higher in multiple myeloma than in controls with both anti-
CD34 and anti-endoglin mAbs. Moreover, patients with low CD34+
MVD survived longer than patients with a higher CD34+ MVD,
whereas there was no difference in the survival of patients with low
and high endoglin+ MVD. Multivariate analysis conﬁrmed the
independent signiﬁcant association between CD34+ MVD and
survival, unlike endoglin+ MVD [136].
All these studies suggest that in solid tumors, MDV measurements
using anti-endoglin antibodies are more sensitive and have better
prognostic value than those using antibodies against other endothelial
markers such as CD34, CD31 or vWF.
3.1.3. Soluble endoglin as a prognostic marker
A number of laboratories have reported increased levels of a
soluble, circulating form of endoglin (Sol-Eng) in serum, plasma or
other ﬂuids from cancer patients as a marker of poor prognosis
(reviewed by Fonsatti et al. [85]). The serum level of Sol-Eng was
signiﬁcantly elevated in patients with metastatic solid malignancies,
mainly breast and colorectal carcinomas, when compared with
healthy individuals or patients with no metastasis [129,159] (see
Table 2). These high levels of serum Sol-Eng decreased in patients
receiving chemotherapy, which restricts the utility of Sol-Eng as a
marker of metastasis and tumor recurrence to the long-term follow-
up of cancer survivors who are not receiving chemotherapy [129].
Recently, Sol-Eng was shown to have independent prognostic value
in serum as an indicator of prostate cancer metastasis to the pelvic
lymph nodes and of biochemical recurrence after radical prostatect-
omy [160,161]. Also, soluble endoglin is a useful urinary marker for
the diagnosis of prostate cancer. Indeed, Sol-Eng increased signiﬁ-
cantly in urine collected after digital rectal examination (whichTable 2
Alterations to TGF-β coreceptors found in human cancer.
TGF-β coreceptor Tumor type Alteration type
Endoglin JP Germline mutation
Prostate carcinoma Downregulation
High levels in plasma (Sol-Eng)
High levels in urine (Sol-Eng)
Esophageal (SCC) Downregulation
Breast carcinoma variants Overexpression
High levels in serum/plasma
(Sol-Eng)
Colorectal carcinoma High levels in serum (Sol-Eng)
AML High levels in serum (Sol-Eng)
CML High levels in serum (Sol-Eng)
Betaglycan Non-Hodgkin's lymphoma Overexpression
BCLL Overexpression
Neuroblastoma Downregulation
Ovarian granulosa Downregulation
Ovarian carcinoma Downregulation
Endometrial carcinoma Downregulation
Prostate carcinoma Downregulation
Breast carcinoma Downregulation
Renal cell carcinoma Downregulation
NSCLC Downregulation
Pancreatic carcinoma Downregulation
JP, juvenile polyposis; DRE, digital rectal examination; SCC, squamous cell carcinoma; AML, ac
leukemia; LOH, loss-of-heterozygosity; NSCLC, non-small cell lung cancer.enriches urine with prostatic secretions) from patients with prostate
cancer when compared to that from healthy men [162]. In the same
study, increased levels of serum Sol-Eng were correlated with an
advanced stage of tumor progression. Elevated levels of Sol-Eng have
also been found in myeloid hematopoietic malignancies, such as
acute myeloid leukemia and chronic myeloproliferative disorders
[163].
The Sol-Eng form is released after proteolytic shedding of the
extracellular domain of membrane-associated endoglin, although
the enzymes involved in the cleavage of the endoglin ectodomain
remain unknown. The origin of the soluble endoglin detected in
cancer patients with metastasis and/or an advanced stage of
disease is somewhat intriguing. The preferential expression of
endoglin in endothelial cells of the tumor vasculature versus
neoplastic cells, has led to the suggestion that Sol-Eng originates
from the neovasculature [85,129,159]. However, our recent data on
mouse skin carcinogenesis (see below) suggest that tumor cells
may also contribute to Sol-Eng [164]. In addition, Sol-Eng is
involved in the pathogenesis of severe vascular diseases, such as
the pregnancy-speciﬁc hypertensive syndrome known as pree-
clampsia [72,165,166] and systemic sclerosis [167], preventing the
binding of TGF-β to its type I and type II signaling receptors and
impairing downstream signaling activity. Moreover, soluble recom-
binant endoglin has been shown to modulate ALK1- and ALK5-
dependent signaling [59,89]. Whether Sol-Eng inﬂuences tumor
development through a similar molecular mechanism remains to
be elucidated.
3.1.4. Diagnostic value of endoglin in imaging techniques
As endoglin is preferentially expressed in the active, angiogenic
endothelium of tumors, the expression of endoglin by the tumor
endotheliummay have diagnostic value if it can be imaged in vivo. The
localization of endoglin to angiogenic tissue could potentially be used
to select patients who would beneﬁt from antiangiogenic therapies
and to measure the response to such a therapy. Optimization of
imaging an endothelial target requires the background blood pool and
ligand extravasation to be minimized. This can be achieved by using
small doses of ligand to ensure that the high-afﬁnity receptors on the
endothelial cells are not saturated and so that images are onlyCorrelation with Observations References
Early onset of disease Low frequency [205]
Metastasis Cell lines [213]
Lymph node metastasis – [160–161]
– Post-DRE [162]
Tumor progression Primary tumors and cell lines [214]
Metastasis MDA-MB-231 cell [222]
Metastasis Sol-Eng levels decrease in
patients receiving chemotherapy
[129,159]
Metastasis Sol-Eng levels decrease in
patients receiving chemotherapy
[129]
– – [163]
– – [163]
Tumor progression QRT-PCR (no protein analyzed) [241]
– Microarray hybridization, RT-PCR [242,243]
Tumor progression – [244]
– Primary tumors and cell lines [247]
Tumor progression Epigenetic silencing [246]
– – [248]
Tumor progression LOH [250]
Invasion and metastasis LOH [253]
Early stages of carcinogenesis Subsequent loss of TβRII
correlates with metastasis
[251]
Tumor progression LOH [252]
Tumor grade – [254,255]
utemyeloid leukemia; CML, chronicmyeloid leukemia; BCLL, B-cell chronic lymphocytic
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must be obtained shortly after injection of the labeled ligand, before
extravasation into the extracellular space has occurred. When fresh
nephrectomy specimens from patients with renal cell carcinomawere
perfused with technetium-99m-labeled anti-endoglin mAbs, the
radiographic hot spots corresponded to tumors previously identiﬁed
by preoperative magnetic resonance in all seven cases studied.
However, in one case technetium-99m-imaging identiﬁed amalignant
mass that was missed on preoperative MRI [168]. These ﬁndings
suggest that 99Tcm-labeled anti-endoglin mAb could be useful to
detect metastatic tumors that conventional imaging modalities are
unable to visualize. Similarly, 125I-labeled anti-endoglin mAb was
injected into two dogs with spontaneous mammary carcinoma and in
images obtained 8 h later, the tumors had rapidly and efﬁciently taken
up radioactivity, with a high signal-to-noise ratio. A diagnosis of ductal
adenocarcinomawas veriﬁed by surgical excision 10 days later and the
dogs showed no systemic side effects during the 3-month follow-up
period [117]. The 111In-labeled rat anti-mouse endoglin mAb injected
intravenously into tumor-bearing mice led to accumulation of radio-
activity in the tumors. Autoradiography and immunohistochemistry
showed the anti-endoglin antibody accumulated at the tumor edge
where the highest density of blood vessels was found, whereas the
tumor's center was heterogeneously stained [169]. Conjugated
microbubbles bearing anti-endoglin mAbs have also been studied
and these conjugates were injected into mice bearing orthotopic
human pancreatic tumors, which were then visualized by ultrasono-
graphy due to their binding to the antibody. The excised tumors were
examined using ﬂuorescent immunohistochemistry after pancrea-
tectomy and found to correlate quantitatively with preoperative
ultrasound ﬁndings [170]. These studies suggest that endoglin is a
good target for tumor imaging and that it may be useful in other
angiogenic diseases. It may be particularly valuable to monitor the
response to antiangiogenic therapies and in situations where
conventional imaging techniques do not give clear results (e.g., to
discriminate between tumor recurrence and postoperative/radio-
therapeutic changes in tissues).
3.1.5. Endoglin as a target for antiangiogenic therapy
Antiangiogenic therapies in tumors theoretically adopt two
different approaches: vascular targeting is a therapy directed at
preexisting blood vessels, whereas antiangiogenic therapy aims to
prevent the development of new vessels in the tumor. Vascular
targeting of agents to treat cancer is designed to cause a rapid and
selective destruction of tumor blood vessels. Unlike antiangiogenic
drugs that inhibit the formation of new vessels, vascular targeting
drugs occlude the pre-existing blood vessels of tumors to cause tumor
cell death by ischemia and extensive hemorrhagic necrosis. Such
approaches have several potential advantages over conventional
chemotherapeutic agents [171,172]. However, a major obstacle in
vascular targeting is the difﬁculty in ﬁnding the appropriate target
that allows us to selectively destroy tumor vasculature without
causing major damage to the normal vasculature of an organ. If
endoglin is speciﬁcally overexpressed in tumor vasculature, endoglin-
expressing cells can be therapeutically targeted as for antitumoral
therapy. However, it has been demonstrated that even though the
staining for endoglin was weaker in normal tissues, all tissues express
endoglin in microvessels at least. Thus, vascular targeting using
endoglin as a target should be carefully re-evaluated as it could also
damage normal vessels [173].
Incubation of human endothelial cells with anti-endoglin mAbs in
vitro signiﬁcantly inhibits growth, mainly in the presence of TGF-β1
[174]. In vivo studies revealed that injecting anti-endoglin mAbs to
mice with breast and colon cancer xenografts was associated with
signiﬁcantly smaller tumors and greater survival rates than in controls
[175,176]. Interestingly, a synergistic effect was reported between
naked anti-endoglin antibodies and conventional chemotherapeuticschedules in a human skin/SCID mouse chimera model [177].
Furthermore, anti-metastatic activity of endoglin speciﬁc antibodies
was observed in lung and liver from mice injected with murine
mammary and colorectal carcinoma cells [178].
Several mechanisms may potentially contribute to the vascular
targeting activity of anti-endoglin mAbs. First, the binding of anti-
endoglin mAbs to membrane endoglin in proliferating endothelial
cells of angiogenic vessels in tumors could block endoglin function,
modifying downstream signaling events, suppressing growth and
even causing the death of the endothelial cells [179]. It should be
noted that cells devoid of endoglin undergo apoptosis in the presence
of TGF-β and hypoxia [81]. A second mechanism could involve the
interaction of the Fc region of the mAb bound to membrane endoglin
and the Fcγ receptors on effector cells, leading to antibody-dependent
cell mediated cytotoxicity or Fc-mediated complement activation.
Such events would result in complement-dependent cytotoxicity and
the subsequent lysis of the target cell. A further possibility is that
soluble endoglin/antibody complexes may be recognized by antigen
presenting dendritic cells leading to antigen-speciﬁc T cell immunity
through a cross-presentation pathway. It was recently reported that
several anti-endoglin mAbs, termed SN6 series mAbs, could suppress
proliferation of human endothelial cells in vitrowithout any accessory
cells [174]. However, little is known about the mechanisms of this
suppression. These in vitro studies show that one mAbmember of this
series, SN6j, induces apoptosis of human endothelial cells in culture,
and this could be a mechanism by which these antibodies suppress
the growth of proliferating endothelial cells. It is also possible that T
cell immunity may be important for antibody-based antiangiogenic
therapy in vivo. This hypothesis was conceived on the basis that anti-
endoglin mAbs were more effective for tumor suppression in T cell
immunocompetent BALB/c mice than in T cell immunodeﬁcient SCID
mice [179].
The use of naked anti-endoglin mAbs as a tumor vascular targeting
agent appears to be clinically relevant since amulticenter phase I clinical
trial using ananti-endoglinmAb (TRC105)was recently approved by the
United States Food and Drug Administration (FDA) and it is now in
progress in patients with advanced and/or metastatic cancer (http://
clinicaltrials.gov/archive/NCT00582985/2008_10_01). Early results
from 17 patients with advanced refractory cancer in this clinical trial
suggest clinical activity and good tolerability of the TRC105 antibody at
doses up to 1 mg/kg every 2 weeks [180].
One alternative to the use of naked anti-endoglin mAbs in vascular
targeting therapy is to conjugate the antibody with toxic molecules in
order to kill the endothelial cell that binds the antibody. Anti-endoglin
mAbs have been conjugated to Auger-electron emitters, which
damage DNA after internalization, and they have been injected into
mice bearing human breast cancers. The treatment reduced tumor
growth in the absence of signiﬁcant toxicity, weight loss or organ
damage [181]. Moreover, when mice bearing human breast cancer
xenografts were treated with anti-endoglin mAbs conjugated to
deglycosylated ricin A, tumor regression was evident in half of the
mice and no progressionwas seen even after 100 days with no further
therapy [175]. Similarly, when anti-endoglin mAbs conjugated to
deglycosylated ricin A were administered to SCID mice with a human
breast cancer (MCF-7) tumor; the immunotoxin completely inhibited
tumor growth in all the treated mice, with no signiﬁcant side effects
[182]. In addition, the non-toxic type II ribosome-inactivating protein
ebulin l has been conjugated to anti-endoglin mAbs, producing a
complex capable of speciﬁcally killing L929 mouse ﬁbroblasts, as well
as L6E9 ratmyoblasts ectopically expressing endoglin, with an efﬁcacy
much higher than ebulin I alone [183]. This conjugate had almost no
effect on cells lacking endoglin expression. Similar results were
obtained by linking anti-endoglin mAbs to the non-toxic type II
ribosome-inactivating protein nigrin b. Immunoﬂuorescence analysis
indicated that the immunotoxin accumulates in a perinuclear region
whereas the antibody was localized at the cell surface [184]. These
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ribosome-inactivating proteins such as ebulin 1 or nigrin b are
promising tools for anticancer therapy, especially due to the very low
toxicity of these proteins in vivo when compared to ricin or other
toxins commonly employed as immunotoxins.
Another approach is to conjugate anti-endoglin mAbs into
packaging molecules, such as adenovirus or cationic liposomes, to
more speciﬁcally deliver their contents to activated endothelial cells,
causing signiﬁcant antitumor activity [185,186]. In addition to the
standard mouse mAb to endoglin, the generation of novel types of
antibodies such as fully synthetic human scFv [187,188] or high-
afﬁnity camelid nanobodies [189] against human endoglin opens up
new and interesting avenues of applications for antiangiogenesis
reagents.
A different therapeutic approach is to sensitize the immune system
of the host against endoglin so that angiogenic vessels are recognized
as an antigen and targeted by the immune system of the host. Using
this approach, a double-attenuated Salmonella-based oral vaccine
containing a murine endoglin-expressing plasmid was administered
to mice bearing a mouse mammary carcinoma [190]. Unvaccinated
mice had signiﬁcantly more lung metastases and their tumors were
more disseminated than in mice receiving the vaccine. Furthermore,
tumors in vaccinated mice were less angiogenic and the vaccinated
mice had a longer overall survival than unvaccinated animals [190].
The immune response against the host endoglin may also be elicited
by using xenogeneic endoglin as a vaccine [191]. Thus, immunother-
apy with porcine endoglin was effective in inducing both protective
and therapeutic antitumor immunity in several mouse tumor models.
The immune response was associated with IgG1 and IgG2b auto-
antibodies against mouse endoglin and the antitumor activity could
be reproduced by the adoptive transfer of the puriﬁed immunoglo-
bulins. Accordingly, endothelial deposition of immunoglobulins and
the inhibition of angiogenesis were observed within the tumors.
Interestingly, the antitumor activity and the production of autoanti-
bodies against mouse endoglin could be abrogated by the depletion of
CD4+ T lymphocytes [191]. Further reﬁnement of the xenogeneic
endoglin protocol includes the combination of recombinant xeno-
geneic endoglin DNA and protein vaccination [192], as well as the
combination of low-dose cisplatin and recombinant xenogeneic
endoglin [193], in both cases producing synergistic cooperation with
enhanced antiangiogenic and antitumor activities.
Taken together, these ﬁndings, suggest that manipulating the
immune response against endoglin appears to be an excellent strategy
for antitumor therapies.
3.2. Endoglin in tumor cells
3.2.1. Endoglin: a susceptibility gene for juvenile polyposis?
Juvenile polyposis (JP) is an autosomal dominant syndrome
characterized by the presence of multiple hamartomatous polyps
that usually appear before 20 years of age [194,195]. Polyps develop in
the colon and rectum, and less often in the upper gastrointestinal
tract. Individuals with JP are at risk of developing malignancies of the
gastrointestinal system at the age of 40–50 years old [196,197]. There
are several predisposing genes for JP, all encoding proteins involved in
TGF-β signaling. Germline mutations of BMPR1A and SMAD4 have
been described in JP patients, each accounting for 20% of cases
[198–200]. SMAD4 mutations appear to predispose to massive upper
gastrointestinal polyps more than BMPR1A mutations [201,202].
Interestingly, some families carrying SMAD4 mutations develop both
JP and HHT [203], an observation that led to the identiﬁcation of
SMAD4 as the third HHT predisposing locus after ENG and ALK1 [204].
Indeed, ENG germline mutations were found in 2 of 14 JP patients who
did not have BMPR1A and SMAD4mutations [205]. The disease had an
early onset in both patients with respect to those without ENG
mutations and no sign of HHT, suggesting ENG as a potential novelsusceptibility gene for JP. The vast majority of the ENG missense
mutations in HHT occur between exons 1 and 9, compared with the
novel JP-related ENG mutations that occur in exons 11 and 12. It
remains unclear whether these ENG mutations lead to haploinsufﬁ-
ciency, like the cause of HHT [206], or to a gain of function.
Nevertheless, while this association of germline ENG mutations with
the development of JP in early childhood was later conﬁrmed, ENG
was not thought to be a susceptibility gene for JP [207]. Accordingly,
Eng heterozygous knockout (Eng+/−) mice exhibit features of HHT
[93], but gastrointestinal polyps were not evident in these mice, nor in
Bmpr1a+/− mice [208]. In contrast, Smad4+/− mice develop gastric
polyposis and adenocarcinoma foci [209].
3.2.2. Endoglin in human sporadic cancer
Endoglin expression has been detected in tumor cells of human
sarcomas melanomas, carcinomas and leukemias [210,211]. In acute
leukemias, endoglin protein is always expressed in themost immature
subtypes and not in more differentiated ones [210]. In tumors of the
melanocytic lineage, endoglin protein was present to a varying degree
in both benign nevi and malignant melanoma, as well as in metastatic
melanoma cell lines [212]. A summary of the alterations to endoglin
expression found in a variety of human tumors and their potential
correlation with tumor progression and metastasis is shown in Table
2. In prostate cancer, endoglin protein levels are reduced in malignant
or metastatic cell lines compared to their non-tumorigenic or less
malignant counterparts [213]. In prostate primary tumors, endoglin
was detected in both prostatic intraepithelial neoplasia andmalignant
areas by immunohistochemistry [127]. Nevertheless, a recent study of
esophageal cancer detected a downregulation of endoglin expression
in primary esophageal squamous cell carcinomas (SCC), as well as in
SCC cell lines [214]. Both epigenetic promoter methylation and loss of
heterozygosity (LOH) appear to contribute to endoglin downregula-
tion in tumor cells. Indeed, the endoglin gene (ENG) maps to
chromosome 9 at 9q34-qter [215], a region (9q33–34) frequently
deleted in esophageal cancer [216,217]. Moreover, overexpression of
endoglin in esophageal squamous carcinoma cells reduced invasive-
ness and tumorigenicity, evidence of a role for endoglin as a tumor
suppressor in esophageal cancer [214]. Similar results were obtained
in prostate cancer cell lines where reduced endoglin levels enhanced
cell migration and invasion [213]. Importantly, these studies point to
endoglin as a key regulator of adhesion, motility and invasion in
human prostate cells. It is worthy of note that among 4,000 genes
evaluated, ENG expression alone was downregulated during the
detachment of metastatic prostate cancer cells [218]. Apparently,
endoglin suppresses prostate cancer cell motility by a TGF-β-
dependent mechanism involving activation of the type I TGF-β
receptor ALK2 and Smad1 [219]. Furthermore, genistein, a soy
isoﬂavone and potential anti-cancer therapeutic agent, inhibited the
invasion of endoglin-deﬁcient prostate cancer cells by activating
ALK2/Smad1 signaling [220].
Besides epithelial cells, endoglin has also been found to modulate
adhesion and migration in ﬁbroblasts [78], endothelial cells [43] and
myoblasts [42]. In endothelial cells, endoglin inhibits cell migration by
antagonizing TGF-β-mediated ERK signaling in a manner dependent
on its ability to interact with the scaffolding protein β-arrestin2 [43].
In myoblasts, endoglin expression also inhibits TGF-β-induced
collagen synthesis by a mechanism involving decreased ERK activa-
tion [221]. In addition, endoglin regulates the organization of the actin
cytoskeleton and focal adhesion sites by interacting with LIM domain-
containing proteins and associated adapter proteins [41,42]. The
physiological relevance of these ﬁndings is unknown at present, but
they reveal the involvement of endoglin in other non-TGF-β related
functions.
Surprisingly, a pro-invasive rather than a suppressor role of
endoglin was recently reported in metastatic breast cancer cells
[222]. High levels of endoglin expression were found in metastatic
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with respect to the parental cells. In breast cancer cells weakly
expressing endoglin, ectopic endoglin overexpression enhanced
migration/invasiveness and induced the formation of invadopodia
[222]. Invadopodia are ﬁnger-like actin-rich protrusions that localize
matrix-degrading metalloproteinases to cell-substratum contact
points and they are related to cancer invasion and metastasis [223].
However, it is unclear whether these effects of endoglin expression in
breast cancer cells are TGF-β-dependent or if they involve other
processes not strictly dependent on TGF-β signaling.
3.2.3. Endoglin in mouse skin chemical carcinogenesis
Multistage mouse skin chemical carcinogenesis is the most
intensively studied in vivo model of carcinogenesis used in almost
all ﬁelds of cancer biology, biochemistry and genetics, to analyze the
nature of tumor initiation, promotion and progression [224,225]. This
model was developed at the beginning of the past century when it
became evident that environmental factors caused sporadic cancer.
Since then, it has been utilized to test chemicals that may cause,
prevent or cure cancer [226], and more recently, to validate the
involvement of genetic events in tumor development through the use
of genetically engineered mice [227,228]. The tumor induction
protocol is quite simple, versatile and reproducible. It involves treating
the dorsal skin of mice with a single dose of a carcinogen (e.g., 7,12-
dimethylbenz(a)anthracene; DMBA), followed by repeated applica-
tions of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate
(TPA). This treatment provokes the appearance of benign papillomas,
more than 90% of which have a speciﬁc oncogenic mutation in the H-
Ras gene [229]. Early papillomas are small and consist of a series ofFig. 5. Schematic representation of tumor development during mouse skin chemical carcino
mutation initiated by 7,12-dimethylbenz(a)anthracene (DMBA). Mutant H-Ras gene dos
alterations that increase tumor growth and malignancy (indicated by the increasing intens
cellular effects of TGF-β1 on the tumor and the stroma are indicated. TGF-β1 exerts contradic
cell growth by activating ALK5/Smad2,3 in the epidermis and thus, TGF-β1 behaves as
keratinocyte cell growth indirectly by mediating the production of inﬂammatory cytokines
carcinogenesis. The relative expression of membrane (mEng) and soluble (Sol-Eng) endog
progression. The effects of Sol-Eng on tumor angiogenesis and stromal cells are unknown. T
shedding potentiates TGF-β1 stimulation of cell migration/invasiveness and EMT.folded epidermal and/or follicular hyperplasias that protrude from
the skin surface [230]. Papillomas progress to malignant squamous
cell carcinomas (SCC) that break through the basement membrane
and progressively invade the underlying dermis, subcutaneous tissue
and muscle. Eventually, these SCCs may result in regional and distant
metastasis. SCCs are characterized by a disorderly proliferation of
keratinocytes with variable degrees of differentiation, and they can be
classiﬁed into three different groups according to the degree of
squamous differentiation: well differentiated (grade I); moderately
differentiated (grade II); and poorly differentiated (grade III/IV).
Some pathologists include spindle cell carcinomas (SpCC) in the group
of poorly differentiated SCCs [230]. SpCC are highly anaplastic tumors
predominantly formed by elongated or spindle-shaped cells that are
considered the latest event in mouse skin carcinogenesis. The
transition from SCC to SpCC correlates with an increase in the ratio
of oncogenic versus normal H-Ras (reviewed by Akhurst and Balmain
[231]), and with the loss or misregulation of the Ink4 locus encoding
the cell cycle regulators p16INK4a, p15INK4b and p19ARF [232,233].
The analysis of endoglin expression in mouse skin tumors and cell
lines revealed that the shedding of membrane endoglin, permitting
the secretion of a Sol-Eng form, is a late event of carcinogenesis
associated with progression from SCCs to SpCCs [164]. Immunohis-
tochemical analysis demonstrated the scattering of a soluble form of
endoglin throughout the stroma and inside the blood vessels of poorly
differentiated SCCs, while a truncated form of endoglin of about
65 kDa was detected in these tumors and in the conditioned medium
of spindle carcinoma cell lines by Western blotting. These studies
showed that the shorter endoglin isoform (S-endoglin) is neither
expressed in normal skin nor in skin tumors, and that it is refractory togenesis. The keratinocyte in the epidermis colored in pink represents a cell with H-Ras
age increases during tumor progression (indicated by font size). Additional genetic
ity of the cell color) are associated with different stages of tumor progression. The key
tory effects on proliferation depending on the cell target. It directly inhibits keratinocyte
a tumor suppressor at early stages of carcinogenesis. By contrast, TGF-β1 stimulates
in the stroma, and thus, it also exhibits a tumor promoting effect even at early stages of
lin is also indicated. Sol-Eng accumulates in the stroma and vessels at late stages of
he mEng behaves as a suppressor of malignancy at late stages of carcinogenesis and its
965C. Bernabeu et al. / Biochimica et Biophysica Acta 1792 (2009) 954–973shedding, highlighting the importance of the cytoplasmic tail of
endoglin for the recognition and activity of speciﬁc proteases. The
functional consequence of the inactivation of membrane-associated
endoglin in squamous carcinoma cells was addressed by using short
hairpin RNA (shRNA) technology. Knockdown of endoglin in SCC cells
activated the ALK5/Smad2,3 signaling, resulting in cell growth
inhibition, delayed tumor latencies and an SCC–SpCC transition
[164]. These results suggest that by attenuating TGF-β/ALK5/
Smad2,3 signaling in keratinocytes endoglin behaves as a suppressor
of malignancy in mouse skin carcinogenesis. Moreover, we propose
that loss-of-function of membrane endoglin must exert strong
selective pressure during tumor progression by priming carcinoma
cells that have lost the TGF-β growth inhibitory response. However,
whether the inactivation of membrane endoglin in SCC cells affects
other TGF-β-independent events remains unexplored, as does the
inﬂuence of soluble endoglin in the evolution and homeostasis of
carcinomas.
These conclusions reached are in accordance with data obtained
from Eng+/− mice. These mice developed less skin tumors than
control Eng+/+ mice, but progression to spindle cell carcinomas was
vastly accelerated upon chemical carcinogenesis [33,234], an identical
phenotype to that observed in transgenic mice overexpressing TGF-β1
in suprabasal layers of the epidermis [235]. These observations ﬁt with
the widely accepted notion of a dual role for TGF-β1 in carcinogenesis
as a tumor suppressor at early stages and a promoter of malignancy at
later stages [9,231]. Nevertheless, this putative suppressor role of TGF-
β1 has been challenged in skin carcinogenesis. Epidermal hyperpro-
liferation was accompanied by inﬂammation in mice in which TGF-β1
expression was targeted to the basal layer of the epidermis [236,237].
Moreover, there was a dramatic reduction in inﬂammation in
knockout mice for Smad3 (Smad3+/− and Smad3−/−) subjected to
skin chemical carcinogenesis, and they were resistant to papilloma
formation and malignant progression [238,239]. These observations
suggest that TGF-β1 has a tumor promoting effect even at early stages
of carcinogenesis, which mediates the inﬂammatory response
produced by TPA during skin promotion [240]. Thus, TGF-β1mediated
production of inﬂammatory cytokines in the stroma may overcome its
growth suppressor effect on epidermal keratinocytes. In the chemical
carcinogenesis studies with Smad3−/− and Eng+/− mice, Smad3 and
endoglin are knocked out in both the epithelia and stroma. The results
with Smad3 knockout mice suggest that this member of the Smad
family is a key mediator of TGF-β1 induced inﬂammation [239]. In the
case of Eng+/− mice, endoglin haploinsufﬁciency in the epithelial
compartment facilitates enhanced Smad2,3 signaling and it appears to
have a stronger effect on tumor growth than endoglin haploinsufﬁ-
ciency in stromal cells.
Fig. 5 summarizes the role of endoglin in tumor development
duringmouse skin chemical carcinogenesis, where TGF-β behaves as a
tumor suppressor at early stages and it exhibits a tumor promoting
effect at late stages of carcinogenesis.
4. Betaglycan in cancer
Altered betaglycan expression has been detected in a variety of
human tumors and the potential correlation with tumor progression
and metastasis is shown in Table 2. Increased expression of
betaglycan and of TGF-β type I and II receptors has been seen in
high-grade non-Hodgkin's lymphomas with respect to low-grade
lymphomas, suggesting a tumor promoting role for these receptors
[241]. Betaglycan expression was also upregulated in B-cell chronic
lymphocytic leukemia with respect to normal B cells [242,243].
However, betaglycan levels are generally downregulated in different
types of cancers. Such reduced betaglycan expression has been
associated with advanced stage neuroblastomas [244], ovarian
carcinomas [245,246], ovarian granulosa cell tumors [247], endome-
trial carcinomas [248], prostate cancer [249,250], renal cell carcino-mas [251], non-small cell lung cancer [252], breast carcinomas [253]
and pancreatic carcinomas [254,255]. Indeed, downregulation or loss
of betaglycan in cancer is a more frequent event than alterations to
any other component of the TGF-β pathway [5]. Several mechanisms
may account for the downregulation of betaglycan during tumor
progression. The betaglycan locus (TGFBR3) is located on the short
arm of chromosome 1 at 1p32, a region frequently deleted in breast,
stomach, colorectal, endometrial, kidney, lung, ovarian and testicular
cancer [256]. LOH at the TGFBR3 locus has been found in about
38–50% of patients with prostate, breast and lung cancer
[250,252,253] pointing to TGFBR3 as a tumor suppressor gene.
Nevertheless, several other potential suppressors' loci, such as TP73
and RUNX3, also reside in this region [257,258]. In the majority of
tumor samples, the low levels or complete absence of betaglycan
protein does not match the genomic data, suggesting that other
mechanisms to downregulate betaglycan expression must be
involved. Combined treatment of ovarian carcinoma cell lines with
inhibitors of methyltransferase and histone deacetylase increased
betaglycan mRNA and protein expression [246], indicating that
epigenetic silencing may play a role, at least in this type of cancer.
Nevertheless, studies directly examining this matter have not yet
been reported. In normal tissues, the expression of TGF-β is relatively
low, sufﬁcient to maintain homeostasis. This situation changes under
conditions of tissue injury and in tumors where the concentration of
TGF-β released by the tumor cells themselves increases, as well as
that released by mesenchymal and inﬂammatory cells of the tumor
stroma [11]. The elevated TGF-β levels in the tumor microenviron-
ment may provoke the downregulation of betaglycan expression
since TGF-β1 negatively regulates betaglycan expression at the
transcriptional level in breast and ovarian cancer cell lines [259].
4.1. Functional studies of betaglycan
The functional role of betaglycan in tumor cells has been assessed
by loss- and gain-of-function approaches. Expression of betaglycan in
MCF-7 andMDA-MB-231 breast cancer cells, both of which synthesize
low amounts of the proteoglycan, restored TGF-β1-induced cell
growth inhibition and reduced either anchorage-independent growth
or tumorigenicity in athymic nude mice [260,261]. Moreover,
increasing betaglycan expression in a murine tumor mammary cell
line inhibited cell invasiveness in vitro and tumor invasion, angiogen-
esis and metastasis in vivo [253]. Similar results were obtained in
humanprostate and ovarian cancer cell lines although these enhanced
betaglycan levels did not affect either cell proliferation or cellular
responsiveness to TGF-β1, but merely decreased cell motility and
invasiveness [246,250]. Conversely, betaglycan knockdown in human
RWPE-1 immortalized prostate epithelial cells led to the acquisition of
transforming capacity in a focus formation assay, although these cells
did not produce tumors in athymic nude mice [249]. The down-
regulation of betaglycan expression in RWPE-1 cells also diminished
the expression of the potent endogenous inhibitor of angiogenesis,
pigment epithelium derived growth factor (PEDGF). Furthermore, the
expansion of the number of cells expressing CD133, a cell surface stem
cell marker, suggested a role for betaglycan in stem cell maintenance
[249]. Together, these ﬁndings are consistent with a suppressor role
for betaglycan in epithelial carcinogenesis.
Betaglycan has also been associated with EMT in development and
cancer. It is required for the EMT events occurring during cardiac
development to form the valves and septa [262], as well as during
palate fusion [263,264]. Accordingly, TGFBR3 null mouse embryos die
due to heart and liver defects [265,266]. It appears that betaglycan is
required in these morphogenetic processes to sustain TGF-β signaling
in the cells undergoing EMT [262,264], whereas in neoplastic cells the
loss of betaglycan facilitates EMT. Thus, upon TGF-β1-induced EMT in
human immortalized keratinocytes and pancreatic carcinoma cell
lines, betaglycan expression is downregulated [255,267], consistent
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Interestingly, maintaining betaglycan expression in pancreatic cancer
cells did not block the TGF-β1-induced loss of E-cadherin or the
cytoskeletal reorganization but rather, stimulation of motility and
invasiveness was suppressed [255]. These results are intriguing and
suggest that: i) downregulation of betaglycan expression is dispen-
sable for TGF-β1-induced EMT but not for TGF-β1-induced cell
migration and invasiveness; and ii) EMT and cell migration, twoFig. 6. Role of endoglin and betaglycan in cancer. (A) The in vivo and in vitro studies refe
suppression and in tumor progression, modulating tumor proliferation, angiogenesis, migrat
highly upregulated during tumor neoangiogenesis. As amarker of neoangiogenesis, endoglin
the soluble form in the serum) and therapeutic (anti-endoglin antibodies and endoglin protei
angiogenesis, probably due to the proangiogenic role of endoglin in endothelial cells. In addi
allowing increased tumor cell migration, invasion and EMT. Therefore, changes in endoglin ex
betaglycan paradox. Most experimental evidence suggests that membrane betaglycan (BG)
signaling as well as by TGF-β-independent mechanisms. However, BG is shed to release a solu
may depend on the extent of shedding, a fact that may explain some discrepancies reported in
tumor development by attenuating TGF-β-induced growth inhibition. On the contrary, enh
human cancer xenograft models.closely related processes, are regulated by distinct mechanisms. A
reduction in betaglycan levels has also been found during the EMT
promoted by HMGI(Y) architectural transcription factors in breast
epithelial cells [268]. Moreover, betaglycan knockdown in preneo-
plastic mouse mammary cells led to decreased expression of E-
cadherin and increased cell growth, motility and invasiveness [269].
More recently, however, a correlation between high levels of
betaglycan and invasiveness was seen in breast cancer cell linesrred to in this review support the involvement of endoglin and betaglycan in tumor
ion, invasion andmetastasis. (B) Endoglin is expressed in endothelial cells (ECs) and it is
may have diagnostic (tumor imaging), prognostic (microvessels staining and in terms of
n as a vaccine) value. (C) Increased endoglin expression correlates with increased tumor
tion, endoglin expression is generally downregulated in tumor cells during progression
pression in both the tumor and the vascular endotheliummodulatemalignancy. (D) The
behaves as a tumor suppressor at early stages of cancerogenesis by enhancing TGF-β
ble form (Sol-BG) that antagonizes TGF-β signaling. Thus, the effect of BG in tumor cells
the literature. High levels of Sol-BG at early stages of tumorigenesis might contribute to
anced levels of Sol-BG at later stages suppress malignancy, as suggested in a variety of
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breast cancer cells impaired the cellular response to TGF-β and
resulted in decreased motility and invasion.
The mechanism by which betaglycan regulates tumor cell
growth, invasion and metastasis has not been fully elucidated.
Betaglycan enhances the binding of all three TGF-β ligands to the
TGF-β signaling receptors and it is essential for the high-afﬁnity cell
surface binding of TGF-β2 [64,271]. Betaglycan also acts as a
coreceptor for inhibin [60] and it mediates signaling of different
members of the BMP subfamily [61]. Obviously, this function of
betaglycan as a ligand-presenting coreceptor resides in the
ectodomain. In addition, a role for the betaglycan cytoplasmic
domain in modulating TGF-β signaling has been highlighted. The
betaglycan endodomain can interact with the autophosphorylated
form of TβRII and it is required for TGF-β2-induced signaling [39]. It
also interacts with Gα-interacting protein which stabilizes betagly-
can on the cell surface [40], and with β-arrestin2 that is involved in
the internalization and degradation of betaglycan and TβRII [38].
The selective advantage of cancer cells that downregulate betagly-
can expression early in carcinogenesis may be due to an attenuated
growth inhibition in response to TGF-β. This has been shown for
breast and renal cancer cell lines in which restoration of betaglycan
expression re-established TGF-β-mediated signaling [251,260]. In
endometrial, ovarian and prostate cancer, loss of betaglycan may
contribute to increase the biological inﬂuence of activin as a
promoter of tumor growth. Inhibin and activin are gonadal
expressed members of the TGF-β superfamily that are crucial for
maintaining normal function in many tissues, particularly those of
the reproductive axis [272]. Inhibin is thought to elicit its
antagonistic action on activin by displacing it from the ActRII,
thereby impairing ActRII from dimerizing with ActRI, although
inhibin must bind to betaglycan to antagonize activin activity [60].
Inhibin has been proposed to have an antagonistic and physiologi-
cally complementary role to androgens, acting as a negative
regulator of prostate growth. Thus, betaglycan downregulation in
prostate cancer results in resistance to inhibin-mediated tumor
suppression [273]. Inhibin resistance as a result of the loss of
betaglycan expression has also been associated with a more
aggressive behavior in epithelial-derived ovarian cancer cell lines
[246,274]. Moreover, targeted deletion of the inhibin α-subunit in
mice results in sex-cord stromal tumors at an early age [275],
suggesting that inhibin acts as a suppressor in ovarian cancer of
stromal origin. On the other hand, the interaction of betaglycan with
cytoplasmic scaffolding proteins, such as Gα-interacting protein and
β-arrestin2, suggests a signaling role that may be independent of
Smad proteins and even of TGF-β. Thus, betaglycan was found to
modulate NFκB activity in association with invasiveness [269,270].
Betaglycan can also activate p38 MAPK signaling in the absence of
TGF-β ligand [276], and recent evidence suggests that the p38 stress
MAPK pathway may suppress tumor progression [277].4.2. Soluble betaglycan
Like endoglin, the extracellular domain of betaglycan can be
proteolytically cleaved to produce a soluble form of betaglycan (Sol-
BG) that sequesters TGF-β ligand antagonizing TGF-β activity
[66,278,279]. Thus, betaglycan may act as a dual modulator of TGF-β
signaling: as a membrane protein it enhances TGF-β activity and as a
soluble form it acts as an inhibitor [66,279]. Indeed, systemic
administration of Sol-BG in human cancer xenograft models antag-
onizes the tumor promoting activities of TGF-β and suppresses tumor
cell growth, invasion and metastasis, as well as tumor angiogenesis
[280–282]. These observations suggest that at least part of the tumor
suppressor effects of betaglycan in human cancer cell lines may be
mediated by Sol-BG [252,253]. In this setting, betaglycan down-regulation in tumors would stimulate malignant progression due to
increased TGF-β activity.
Its role as an inhibitor of tumor growth, invasion and metastasis
makes Sol-BG a promising agent to be used in cancer therapy. Several
approaches to inhibit TGF-β signaling have been explored including
antisense oligonucleotides, drugs that inhibit the kinase activity of
TβRI and antagonists that block the binding of ligands to TGF-β
receptors [283]. This latter strategy seems to be the most favorable
approach, as inhibiting TGF-β extracellularly avoids the need for the
internalization of the agent, and it can block TGF-β signaling that is
independent of TβRI. Thus, methods to increase the ligand afﬁnity of
Sol-BG and its ability to inhibit the activity of all three TGF-β isoforms
are currently being designed in order to improve the efﬁcacy of Sol-BG
in cancer therapy [284].
5. Concluding remarks
The TGF-β signaling pathway plays a key role in a plethora of
physiological processes such as development, cellular proliferation,
extracellular matrix synthesis, angiogenesis or immune response,
whose dysregulation may result in tumor development. The TGF-β
coreceptors endoglin and betaglycan are modulators of the TGF-β
responsewith important roles in cancer (Fig. 6). Endoglin upregulated
expression in tumor-associated vascular endothelium has revealed its
prognostic and diagnostic value in solid tumors, as well as its potential
as a vascular target for antiangiogenic cancer therapy. In addition,
functional studies on the role of endoglin and betaglycan in the tumor
cells themselves have demonstrated their critical role as tumor
suppressors during cancer progression. While much more work
must be done to fully understand the molecular mechanisms that
underlie the role of endoglin and betaglycan in tumor angiogenesis
and malignancy, the recent advances provide new research avenues
for better diagnosis, prognosis and therapy in cancer.
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